|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
1,095,971,000 |
Market
Cap: |
18.19(B) |
Last
Volume: |
6,583,979 |
Avg
Vol: |
10,637,630 |
52
Week Range: |
$7.2 - $17.09 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ-100 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Teva Pharmaceutical Industries is a pharmaceutical company. Co. operates through three segments: North America, which includes the U.S. and Canada; Europe, which includes the European Union and certain other European countries; and International Markets, which includes all countries in which Co. operates other than those in Co.'s North America and Europe segments. Co.'s products include: AUSTEDO; AJOVY (anti calcitonin gene-related peptide); COPAXONE; BENDEKA and TREANDA; ProAir HFA; ProAir RespiClick; QVAR; QVAR RediHaler; ProAir Digihaler; ArmonAir Digihaler; AirDuo Digihaler; BRALTUS®; CINQAIR/CINQAERO; and AirDuo RespiClick.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
441,140 |
720,697 |
810,545 |
1,346,844 |
Total Sell Value |
$6,065,172 |
$9,700,206 |
$10,499,443 |
$15,688,359 |
Total People Sold |
8 |
8 |
8 |
10 |
Total Sell Transactions |
14 |
17 |
20 |
34 |
End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Dethlefs Sven |
EVP Global Marketing&Portfolio |
|
2018-03-19 |
4 |
S |
$17.88 |
$10,208 |
D/D |
(571) |
4,445 |
|
- |
|
Stark David Matthew |
Exec. VP Chief Legal Officer |
|
2018-03-19 |
4 |
AS |
$18.38 |
$43,340 |
D/D |
(2,358) |
2,974 |
|
- |
|
Griffin Deborah A |
Chief Accounting Officer |
|
2018-03-19 |
4 |
S |
$17.88 |
$16,859 |
D/D |
(943) |
0 |
|
- |
|
Nazzi Gianfranco |
EVP, Growth Markets Commercial |
|
2018-03-19 |
4 |
S |
$17.89 |
$8,177 |
D/D |
(457) |
5,746 |
|
- |
|
Fridriksdottir Hafrun |
Executive VP, Global R&D |
|
2018-03-19 |
4 |
S |
$17.88 |
$6,222 |
D/D |
(348) |
7,051 |
|
- |
|
Ogrady Brendan P. |
EVP, North America Commercial |
|
2018-03-19 |
4 |
S |
$17.88 |
$21,078 |
D/D |
(1,179) |
1,388 |
|
- |
|
Daniell Richard |
Exec. VP, European Commercial |
|
2018-03-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,297 |
1,297 |
|
- |
|
Mcclellan Michael James |
EVP, Chief Financial Officer |
|
2018-03-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
660 |
11,582 |
|
- |
|
Dethlefs Sven |
EVP Global Marketing&Portfolio |
|
2018-03-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,179 |
5,016 |
|
- |
|
Stark David Matthew |
Exec. VP Chief Legal Officer |
|
2018-03-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,358 |
5,332 |
|
- |
|
Griffin Deborah A |
Chief Accounting Officer |
|
2018-03-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
943 |
943 |
|
- |
|
Nazzi Gianfranco |
EVP, Growth Markets Commercial |
|
2018-03-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
872 |
6,203 |
|
- |
|
Fridriksdottir Hafrun |
Executive VP, Global R&D |
|
2018-03-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,012 |
7,399 |
|
- |
|
Ogrady Brendan P. |
EVP, North America Commercial |
|
2018-03-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,179 |
2,567 |
|
- |
|
Griffin Deborah A |
Chief Accounting Officer |
|
2018-03-12 |
4 |
S |
$19.49 |
$18,554 |
D/D |
(952) |
0 |
|
- |
|
Griffin Deborah A |
Chief Accounting Officer |
|
2018-03-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
952 |
952 |
|
- |
|
Stark David Matthew |
Exec. VP Chief Legal Officer |
|
2018-03-12 |
4 |
AS |
$19.20 |
$46,867 |
D/D |
(2,441) |
2,974 |
|
- |
|
Stark David Matthew |
Exec. VP Chief Legal Officer |
|
2018-03-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,441 |
5,415 |
|
- |
|
Daniell Richard |
Exec. VP, European Commercial |
|
2018-03-12 |
4 |
S |
$19.50 |
$13,922 |
D/D |
(714) |
0 |
|
- |
|
Daniell Richard |
Exec. VP, European Commercial |
|
2018-03-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
714 |
714 |
|
- |
|
Ogrady Brendan P. |
EVP, North America Commercial |
|
2018-03-12 |
4 |
S |
$19.49 |
$14,383 |
D/D |
(738) |
1,388 |
|
- |
|
Ogrady Brendan P. |
EVP, North America Commercial |
|
2018-03-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
738 |
2,126 |
|
- |
|
Nazzi Gianfranco |
EVP, Growth Markets Commercial |
|
2018-03-12 |
4 |
S |
$19.50 |
$8,989 |
D/D |
(461) |
5,331 |
|
- |
|
Nazzi Gianfranco |
EVP, Growth Markets Commercial |
|
2018-03-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
880 |
5,792 |
|
- |
|
Dethlefs Sven |
EVP Global Marketing&Portfolio |
|
2018-03-12 |
4 |
S |
$19.49 |
$11,226 |
D/D |
(576) |
3,837 |
|
- |
|
524 Records found
|
|
Page 20 of 21 |
|
|